Scaffold-based tissue engineering approaches in treating infertility.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Jan 2020
Historique:
received: 05 09 2019
revised: 03 11 2019
accepted: 12 11 2019
pubmed: 19 11 2019
medline: 14 1 2020
entrez: 19 11 2019
Statut: ppublish

Résumé

Tissue engineering and the use of scaffolds have shown high therapeutic potentialities about male and female infertility. Nowadays, many couples are suffering from infertility problems. There are different causes for infertility including chemotherapy (for male and female), uterine injuries, and intrauterine adhesions. Extra-cellular matrix in tissue engineering provides a supportive medium for blood or lymphatic vessels making it a suitable substrate for cell implantation and growth. Dominant successes in this branch have been in use of patient-derived primary cells, these cells loaded in scaffolds and used to generate tissue for re-implantation. However, this method has limitations, because of the invasive nature of cell collection, also the cells patient-derived may be not healthy and become the source of disease. Therefore, use of stem cells, including embryonic stem (ES) cells, bone marrow mesenchymal stem cells (BM-MSCs) and umbilical cord-derived mesenchymal stem cells (UC-MSCs) have been considered. Cell/scaffold systems have a substantial role in fertility organs or agents repair or regeneration. This review summarizes the novel scaffold-based tissue engineering approaches to treat infertility.

Identifiants

pubmed: 31738881
pii: S0024-3205(19)30993-2
doi: 10.1016/j.lfs.2019.117066
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117066

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Yalda Jahanbani (Y)

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Soudabe Davaran (S)

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Maryam Ghahremani-Nasab (M)

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Leili Aghebati-Maleki (L)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: aghebatil@tbzmed.ac.ir.

Mehdi Yousefi (M)

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: yousefime@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH